v3.24.3
License and Acquisition Agreements - Biogen Asset Purchase Agreement (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2022
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
License and Acquisition Agreements              
Uncured period which causes termination of the agreement, due to insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured   90 days          
Notice period to terminate the agreement under payment-related breaches   30 days          
Research and development       $ 26,057 $ 17,106 $ 76,408 $ 56,045
Maximum              
License and Acquisition Agreements              
Royalty rate increase (percentage) 1.00%            
Asset purchase agreement | Biogen              
License and Acquisition Agreements              
Remaining milestone payments to be paid upon clinical and regulatory milestone achievement       165,000   165,000  
Maximum aggregate obligation to pay insignificant annual maintenance fees as well as clinical and regulatory milestone payments     $ 1,575        
Notice period to terminate the agreement     90 days        
Uncured period which causes termination of the agreement, due to insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured     90 days        
Notice period to terminate the agreement under payment-related breaches     30 days        
Research and development       72 $ 49 144 $ 83
Asset purchase agreement | Biogen | Maximum              
License and Acquisition Agreements              
Milestone payment to be paid upon clinical and regulatory milestone achievement       179,000   179,000  
Milestone payment to be paid upon net sales milestone achievement       $ 150,000   $ 150,000